Blood Test Plus 10-Minute App Could Catch Alzheimer's Years Before Symptoms Appear

Alzheimer's disease has a well-documented timing problem: neurodegeneration typically begins years or even decades before anyone receives a diagnosis. Newer drugs that target the disease's underlying biology are most effective when given early, yet most diagnoses still arrive late. Two companies — Circular Genomics and Altoida — announced a collaboration designed to close that gap from opposite ends of the diagnostic spectrum.

Altoida's Digital NeuroMarker platform takes roughly 10 minutes, can be self-administered, and uses AI combined with augmented reality to track subtle changes in motor function, speech, and cognition during everyday tasks. Circular Genomics' CircPath blood test reads circulating RNA (circRNA) signatures associated with neurodegeneration and disease progression. The combined workflow places the cognitive app first — accessible in a primary care setting — and reserves the blood test for patients who show early signs of decline, making the process far more scalable than traditional neuropsychological batteries that require specialist time and hours of testing.

The evidence base for each tool is credible. Circular Genomics published data in Nature Medicine showing its circRNA signature can predict progression to symptomatic Alzheimer's years before clinical onset, complementing rather than replacing existing amyloid and tau biomarkers. Altoida's platform has peer-reviewed support in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, with Altoida now preparing a pivotal study aimed at FDA clearance.

The scale of the opportunity is striking: an estimated 200 million people worldwide are thought to have undiagnosed mild cognitive impairment, many of whom could qualify for emerging Alzheimer's therapies if identified in time. Diagnostic capacity, not drug availability, may prove to be the real bottleneck in the next decade of Alzheimer's care.

For longevity-focused readers, the implication is clear: extending healthy cognitive years depends on building practical diagnostic pathways that intercept people before irreversible neurodegeneration accumulates. Real-world pilots of the combined workflow are expected to launch before year's end.